Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2023 08:05 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
October 16, 2023 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
September 27, 2023 07:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases

Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa is advancing a dynamic pipeline of drug candidates with...
July 19, 2023 06:00 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters...
April 20, 2023 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
March 15, 2023 16:11 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product...
March 01, 2023 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

CORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
December 19, 2022 16:10 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development...
November 07, 2022 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...